NCT04451837View on ClinicalTrials.gov

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

December 15, 2021

Study Completion Date

December 31, 2026

Conditions
Type2 Diabetes
Interventions
DRUG

Semaglutide

Ozempic s.c. once weekly for 6 months

DRUG

Dapagliflozin

Forxiga 10 mg p.o. once daily for 6 months

Trial Locations (1)

20502

Anders Rosengrentest, Malmo

All Listed Sponsors
collaborator

Göteborg University

OTHER

lead

Region Skane

OTHER